← Back to Search

PD-L1 Inhibitor

PF-07225570 for Bladder Cancer

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No evidence of upper tract urothelial cancer or cancer within the prostatic urethra as documented by imaging studies performed within 6 months of enrollment
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 3 years
Awards & highlights

Study Summary

This trial is testing a new drug, PF-07225570, to see if it is safe and effective against bladder cancer when used alone or in combination with another drug.

Eligible Conditions
  • Bladder Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with AEs according to Relationship
Number of Participants with AEs according to Seriousness
Number of Participants with Adverse Events (AEs) according to Severity
+1 more
Secondary outcome measures
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-07225570 after a single dose
Area under the curve from specified time to steady state (AUCτ,ss) of PF-07225570 after multiple doses
Concentration from maximum to steady state (Cmax,ss) of PF-07225570 after multiple doses
+14 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Part 2B PF-07225570 and sasanlimabExperimental Treatment2 Interventions
PF-07225570 IVe and sasanlimab SQ Combination Dose Expansion
Group II: Part 2A PF-07225570 monotherapyExperimental Treatment1 Intervention
IVe Single Agent Dose Expansion
Group III: Part 1B PF-07225570 and sasanlimabExperimental Treatment2 Interventions
PF-07225570 IVe and sasanlimab Subcutaneous (SQ) Combination Dose Escalation
Group IV: Part 1A PF-07225570 monotherapyExperimental Treatment1 Intervention
Intravesical (IVe) Single Agent Dose Escalation

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,556 Previous Clinical Trials
10,907,683 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,467 Previous Clinical Trials
8,089,120 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025